The project team will evaluate the scientific landscape for a set of neurodevelopmental and neuropsychiatric diseases, and construct a therapeutic discovery plan that leverages the capabilities of a state-of-the-art cerebral organoid and machine learning-driven drug discovery platform. The team will utilize secondary research to synthesize current disease mechanism hypotheses and nominate novel therapeutic targets or approaches to be evaluated using the discovery platform. The team will incorporate multiple factors into the final therapeutic discovery strategy, including: i) molecular, cellular, and systems-level disease biology, ii) clinical disease characteristics, iii) preclinical and clinical-stage therapies in development, and iv) historical clinical trial results. The BCBA team will construct a white paper report summarizing their findings and providing recommendations to guide the client’s business strategy. Throughout the project, team members will interact directly with the company’s executives, an industry mentor, and Biotech Connection – Bay Area leadership.